Fact CheckerSign in

NCT05848700CompletedPhase 1

A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate SEP-363856 Physical Dependence in Adult Subjects With Schizophrenia

Source: ClinicalTrials.gov · Last updated 26 Jun 2024

Brief summary (registry, in English)

A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
60 (actual)
First submitted
27 Apr 2023
Start date
21 Jun 2023
Primary completion date
15 Mar 2024
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
NCT number
NCT05848700

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 60
  • From 21 Jun 2023 to the primary completion date, 15 Mar 2024
  • 7 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Subject has attempted suicide within 6 months prior to Screening.
  • Subject answers "yes" to "Suicidal Ideation" Item 4 (active suicidal ideation with some intent to act, without specific plan) or Item 5 (active suicidal ideation with specific plan and intent) on the Columbia Suicide Severity Rating Scale (C-SSRS) at Screening (ie, in the past 1 month) or at any subsequent C-SSRS assessment prior to dosing (ie, since last visit).

Other

  • Subject has a DSM-5 diagnosis or presence of symptoms consistent with a current DSM-5 diagnosis other than schizophrenia.
  • Subject is at significant risk of harming him/herself or others (passive or active) according to the Investigator's judgment.

Who the study is looking for

  • Male or female subject between 18 and 65 years of age (inclusive) at the time of informed consent.
  • Subject meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a primary diagnosis of schizophrenia as established by clinical interview (using the DSM-5 as a reference and confirmed using the Structured Clinical Interview for DSM-5, Clinical Trials Version \[SCID-CT\]).
  • Subject must have a Clinical Global Impression-Severity Scale (CGI-S) score ≤ 4 (normal to moderately ill) at Screening and Day 1.
  • Subject must have a PANSS total score ≤ 80 at Screening and a score of ≤ 4 on the following PANSS items at Screening: P7 (hostility) and G8 (uncooperativeness).
  • Subject has been taking an antipsychotic for at least 6 weeks prior to Screening and has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes may be permitted) for at least 6 weeks prior to Screening.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (7)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Atlanta Center for Medical Research
Coordinator of this site? Confirm its status
AtlantaUnited StatesUnknown status
Woodland International Research Group LLC
Coordinator of this site? Confirm its status
Little RockUnited StatesUnknown status
Behavioral Clinical Research, Inc.
Coordinator of this site? Confirm its status
Miami LakesUnited StatesUnknown status
Neuro-Behavioral Clinical Research Inc.
Coordinator of this site? Confirm its status
North CantonUnited StatesUnknown status
Research Centers of America at Fort Lauderdale Behavioral Health Center
Coordinator of this site? Confirm its status
Oakland ParkUnited StatesUnknown status
Pillar Clinical Research, LLC
Coordinator of this site? Confirm its status
RichardsonUnited StatesUnknown status
Woodland Research Northwest
Coordinator of this site? Confirm its status
RogersUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.